Lyme Disease and Co-Infection Infection Testing

  Strengths of Vibrant Immunochip and Chemiluminescence-based Antibody detection Patients in early stages of Lyme disease and those who have been treated with antibiotics may not exhibit detectable levels of antibody using traditional methods such as ELISA. For low analyte concentrations such as this, chemiluminescence-based immunoassays are the assays of choice because they enable a more sensitive detection.The chemiluminescence-based assay on the Vibrant platform enables the detection oflower level of antibodies in comparison to the ELISA testing available currently in othercommercial labs. Comparison of chemiluminescence based assays and ELISA based assays have shown the superiority of the former particularly in the case of Lyme disease.    Published Accuracy You Can Trust 91% Sensitivity 99% Specificity 95%  Reproducibility 4  CDC Validations - Vibrant is the only lab to have completed all four rounds of CDC sample validation, including both non-blinded and blinded  sample verifi